Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
...
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Faculty Hospital Kralovske Vinohrady
- Target Recruit Count
- 605
- Registration Number
- NCT03551964
- Locations
- 🇨🇿
University Hospital Kralovske Vinohrady, Prague, Please Select, Czechia
🇨🇿St. Anne's University Hospital Brno, Brno, Czechia
🇨🇿Department of Cardiology, University Hospital Brno-Bohunice, Brno, Czechia
PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT03492931
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study
- First Posted Date
- 2018-04-06
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 14
- Registration Number
- NCT03489863
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
- Conditions
- Interventions
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
- Target Recruit Count
- 120
- Registration Number
- NCT03487406
- Locations
- 🇬🇧
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Daily Variability of Platelet Aggregation in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Collegium Medicum w Bydgoszczy
- Target Recruit Count
- 73
- Registration Number
- NCT03454841
- Locations
- 🇵🇱
Department of Cardiology, Wrocław Medical University, Wrocław, Dolnośląskie, Poland
🇵🇱Department of Cardiology, Dr. A. Jurasz University Hospital, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Kujawsko-pomorskie, Poland
Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI
- Conditions
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 40
- Registration Number
- NCT03437044
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI
- Conditions
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- AORTICA Group
- Target Recruit Count
- 61
- Registration Number
- NCT03435133
- Locations
- 🇪🇸
Pedro Dorado, Salamanca, Spain
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 77
- Registration Number
- NCT03430661
- Locations
- 🇺🇸
Biotrial Inc, Newark, New Jersey, United States
Efficacy and Safety of Low-dose Ticagrelor
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2019-09-30
- Target Recruit Count
- 3043
- Registration Number
- NCT03381742
- Locations
- 🇨🇳
Thromboela-Stogram, Beijing, China
TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Target Recruit Count
- 514
- Registration Number
- NCT03357874
- Locations
- 🇫🇷
APHM, Marseille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.